Advertisement

Duloxetine Versus Placebo in Patients With Chronic Low Back Pain: A 12-Week, Fixed-Dose, Randomized, Double-Blind Trial

      Abstract

      This randomized, double-blind, placebo-controlled study assessed efficacy and safety of duloxetine in patients with chronic low back pain (CLBP). Adults (n = 401) with a nonneuropathic CLBP and average pain intensity of ≥4 on an 11-point numerical scale (Brief Pain Inventory [BPI]) were treated with either duloxetine 60 mg once daily or placebo for 12 weeks. The primary measure was BPI average pain. Secondary endpoints included Patient's Global Impressions of Improvement (PGI-I), Roland Morris Disability Questionnaire (RMDQ-24), BPI-Severity (BPI-S), BPI-Interference (BPI-I), and response rates (either ≥30% or ≥50% BPI average pain reduction at endpoint). Health outcomes included Short Form-36, European Quality of Life–5 Dimensions, and the Work Productivity and Activity Impairment questionnaire. Safety and tolerability were assessed. Compared with placebo-treated patients, duloxetine-treated patients reported a significantly greater reduction in BPI average pain (P ≤ .001). Similarly, duloxetine-treated patients reported significantly greater improvements in PGI-I, BPI-S, BPI-I, 50% response rates, and some health outcomes. The RMDQ and 30% response rate showed numerical improvements with duloxetine treatment. Significantly more patients in the duloxetine group (15.2%) than patients in the placebo group (5.4%) discontinued because of adverse events (P = .002). Nausea and dry mouth were the most common treatment-emergent adverse events with rates significantly higher in duloxetine-treated patients.

      Perspective

      This study provides clinical evidence of the efficacy and safety of duloxetine at a fixed dose of 60 mg once daily in the treatment of chronic low back pain (CLBP). Duloxetine received approval for treatment of CLBP in November, 2010.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The Journal of Pain
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Airaksinen O.
        • Brox J.I.
        • Cedraschi C.
        • Hildebrandt J.
        • Klaber-Moffett J.
        • Kovacs F.
        • Mannion A.F.
        • Reis S.
        • Staal J.B.
        • Ursin H.
        • Zanoli G.
        COST B13 Working Group on Guidelines for Chronic Low Back Pain: European guidelines for the management of chronic nonspecific low back pain.
        Eur Spine J. 2006; 15: 192-300
        • Andersson G.B.
        Epidemiology of low back pain.
        Acta Orthop Scand Suppl. 1998; 281: 28-31
        • Andersson G.B.
        Epidemiological features of chronic low-back pain.
        Lancet. 1999; 354: 581-585
        • Arnold L.M.
        Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
        Pain Med. 2007; 8: S63-S74
        • Arnold L.M.
        • Pritchett Y.L.
        • D'Souza D.N.
        • Kajdasz D.K.
        • Iyengar S.
        • Wernicke J.F.
        Duloxetine for the treatment of fibromyalgia in women: Pooled results from two randomized, placebo-controlled clinical trials.
        J Womens Health (Larchmt). 2007; 16: 1145-1156
        • Chang V.
        • Gonzalez P.
        • Akuthota V.
        Evidence-informed management of chronic low back pain with adjunctive analgesics.
        Spine J. 2008; 8: 21-27
        • Chappell A.S.
        • Ossanna M.J.
        • Liu-Seifert H.
        • Iyengar S.
        • Skljarevski V.
        • Li L.C.
        • Bennett R.M.
        • Collins H.
        Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13-week, randomized, placebo-controlled trial.
        Pain146. 2009; : 253-260
        • Chou R.
        • Huffman L.H.
        Medications of acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians Clinical Guideline.
        Ann Intern Med. 2007; 147: 505-514
        • Coderre T.J.
        • Katz J.
        Peripheral and central hyperexcitability: Differential signs and symptoms in persistent pain.
        Behav Brain Sci. 1997; 20: 404-419
        • Cohen S.P.
        • Argoff C.E.
        • Carragee E.J.
        Management of low back pain.
        BMJ. 2008; 337: a2718
        • Deyo R.A.
        • Weinstein J.N.
        Low back pain.
        N Engl J Med. 2001; 344: 363-370
        • Dworkin R.H.
        • Turk D.C.
        • McDermott M.P.
        • Peirce-Sandner S.
        • Burke L.B.
        • Cowan P.
        • Farrar J.T.
        • Hertz S.
        • Raja S.N.
        • Rappaport B.A.
        • Rauschkolb C.
        • Sampaio C.
        Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations.
        Pain. 2009; 146: 238-244
        • Dworkin R.H.
        • Turk D.C.
        • Wyrwich K.W.
        • Beaton D.
        • Cleeland C.S.
        • Farrar J.T.
        • Haythornthwaite J.A.
        • Jensen M.P.
        • Kerns R.D.
        • Ader D.N.
        • Brandenburg N.
        • Burke L.B.
        • Cella D.
        • Chandler J.
        • Cowan P.
        • Dimitrova R.
        • Dionne R.
        • Hertz S.
        • Jadad A.R.
        • Katz N.P.
        • Kehlet H.
        • Kramer L.D.
        • Manning D.C.
        • McCormick C.
        • McDermott M.P.
        • McQuay H.J.
        • Patel S.
        • Porter L.
        • Quessy S.
        • Rappaport B.A.
        • Rauschkolb C.
        • Revicki D.A.
        • Rothman M.
        • Schmader K.E.
        • Stacey B.R.
        • Stauffer J.W.
        • von Stein T.
        • White R.E.
        • Witter J.
        • Zavisic S.
        Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations.
        J Pain. 2008; 9: 105-121
        • Freburger J.K.
        • Holmes G.M.
        • Agans R.P.
        • Jackman A.M.
        • Darter J.D.
        • Wallace A.S.
        • Castel L.D.
        • Kalsbeek W.D.
        • Carey T.S.
        The rising prevalence of chronic low back pain.
        Arch Intern Med. 2009; 169: 251-258
        • Frymoyer J.W.
        Back pain and sciatica.
        N Engl J Med. 1988; 318: 291-300
        • Frymoyer J.W.
        Predicting disability from low back pain.
        Clin Orthop Relat Res. 1992; 279: 101-109
        • Guy W.
        ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare publication (ADM). Rockville, MD.
        National Institute of Mental Health. 1976; : 76-338
        • Hayden J.A.
        • van Tulder M.W.
        • Tomlinson G.
        Systematic review: Strategies for using exercise therapy to improve outcomes in chronic low back pain.
        Ann Intern Med. 2005; 142: 776-785
        • Keller S.
        • Bann C.M.
        • Dodd S.L.
        • Schein J.
        • Mendoza T.R.
        • Cleeland C.S.
        Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain.
        Clin J Pain. 2004; 20: 309-318
        • Kind P.
        The EuroQoL instrument: An index of health-related quality of life.
        in: Spilker B. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Lippincott-Raven Publishers, Philadelphia1996: 191-201
        • Krismer M.
        • van Tulder M.
        Low Back Pain Group of the Bone and Joint Health Strategies for Europe Project: Strategies for prevention and management of musculoskeletal conditions. Low back pain (non-specific).
        Best Pract Res Clin Rheumatol. 2007; 21: 77-91
        • Machado L.A.
        • Kamper S.J.
        • Herbert R.D.
        • Maher C.G.
        • McAuley J.H.
        Analgesic effects of treatments for non-specific low back pain: A meta-analysis of placebo-controlled randomized trials.
        Rheumatology (Oxford). 2009; 48: 520-527
        • Manchikanti L.
        Epidemiology of low back pain.
        Pain Physician. 2000; 3: 167-192
        • Manchikanti L.
        • Singh V.
        • Datta S.
        • Cohen S.P.
        • Hirsch J.A.
        Comprehensive review of epidemiology, scope, and impact of spinal pain.
        Pain Physician. 2009; 12: E35-E70
        • Martell B.A.
        • O'Connor P.G.
        • Kerns R.D.
        • Becker W.C.
        • Morales K.H.
        • Kosten T.R.
        • Fiellin D.A.
        Systematic review: Opioid treatment for chronic back pain: Prevalence, efficacy, and association with addiction.
        Ann Intern Med. 2007; 146: 116-127
      1. Multi-Health Systems (MHS) Inc: POMS Brief Form. 2003

        • Posner K.
        • Melvin G.A.
        • Stanley B.
        • Oquendo M.A.
        • Gould M.
        Factors in the assessment of suicidality in youth.
        CNS Spectr. 2007; 12: 156-162
        • Posner K.
        • Oquendo M.A.
        • Gould M.
        • Stanley B.
        • Davies M.
        Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants.
        Am J Psychiatry. 2007; 164: 1035-1043
        • Raskin J.
        • Pritchett Y.L.
        • Wang F.
        • D'Souza D.N.
        • Waninger A.L.
        • Iyengar S.
        • Wernicke J.F.
        A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.
        Pain Med. 2005; 6: 346-356
        • Reilly M.C.
        • Zbrozek A.S.
        • Dukes E.M.
        The validity and reproducibility of a work productivity and activity impairment instrument.
        Pharmacoeconomics. 1993; 4: 353-365
        • Ricci J.A.
        • Stewart W.F.
        • Chee E.
        • Leotta C.
        • Foley K.
        • Hochberg M.C.
        Back pain exacerbations and lost productive time costs in the United States workers.
        Spine. 2006; 31: 3052-3060
        • Robinson M.J.
        • Edwards S.E.
        • Iyengar S.
        • Bymaster F.
        • Clark M.
        • Katon W.
        Depression and pain.
        Front Biosci. 2009; 14: 5031-5051
        • Roland M.
        • Morris R.
        A study of the natural history of back pain, I: Development of a reliable and sensitive measure of disability in low-back pain.
        Spine. 1983; 8: 141-144
        • Skljarevski V.
        • Ossanna M.
        • Liu-Seifert H.
        • Zhang Q.
        • Chappell A.
        • Iyengar S.
        • Detke M.
        • Backonja M.
        A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.
        Eur J Neurol. 2009; 16: 1041-1048
        • Skljarevski V.
        • Zhang S.
        • Chappell A.S.
        • Detke M.
        • Murray I.
        • Backonja M.
        Maintenance of effect of duloxetine in patients with chronic low back pain.
        Eur J Pain. 2009; 13: s195
        • Tan G.
        • Jensen M.P.
        • Thornby J.I.
        • Shanti B.F.
        Validation of the Brief Pain Inventory for chronic nonmalignant pain.
        J Pain. 2004; 5: 133-137
        • Ware J.E.
        • Snow K.K.
        • Kosinski M.
        • Gandek B.
        SF-36 Health Survey Manual and Interpretation Guide.
        The Health Institute, New England Medical Center, Boston, MA1993
        • Wernicke J.F.
        • Pritchett Y.L.
        • D'Souza D.N.
        • Waninger A.
        • Tran P.
        • Iyengar S.
        • Raskin J.
        A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
        Neurology. 2006; 67: 1411-1420